First Mercantile Trust’s Fate Therapeutics FATE Stock Holding History

First Mercantile Trust’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$40K	Hold	680	–	–	0.01%	790
2021 Q2	$59K	Sell	680 -83	-11%	-$6.69K	0.01%	779
2021 Q1	$63K	Sell	763 -131	-15%	-$12.6K	0.01%	761
2020 Q4	$81K	Buy	+894	New	+$55.5K	0.01%	731
2020 Q2	–	Sell	-5,700	Closed	-$127K	–	887
2020 Q1	$127K	Sell	5,700 -250	-4%	-$6.32K	0.02%	487
2019 Q4	$116K	Sell	5,950 -8,575	-59%	-$136K	0.01%	637
2019 Q3	$226K	Sell	14,525 -10	-0.1%	-$192	0.02%	448
2019 Q2	$295K	Buy	14,535 +73	+0.5%	+$1.32K	0.03%	320
2019 Q1	$254K	Sell	14,462 -665	-4%	-$10.5K	0.06%	377
2018 Q4	$194K	Sell	15,127 -2,307	-13%	-$32.2K	0.05%	436
2018 Q3	$284K	Buy	17,434 +4,535	+35%	+$53.6K	0.06%	391
2018 Q2	$146K	Buy	12,899 +6,863	+114%	+$75.6K	0.03%	606
2018 Q1	$59K	Buy	+6,036	New	+$57.8K	0.01%	727

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

First Mercantile Trust's FATE Position: Q3 2021 in Review

First Mercantile Trust held its Fate Therapeutics (FATE) position steady in Q3 2021 at 680 shares worth $40K. The position accounts for 0.01% of the portfolio, ranked #790.

First Mercantile Trust first reported a position in FATE in Q1 2018 and has held it in 13 quarters since. The position peaked at $295K in Q2 2019. 265 funds tracked by Wall St. Rank hold FATE as of Q3 2021.

First Mercantile Trust held 680 shares of Fate Therapeutics worth $40K as of Q3 2021.
First Mercantile Trust left its Fate Therapeutics share count unchanged in Q3 2021.
Fate Therapeutics made up 0.01% of First Mercantile Trust's portfolio in Q3 2021, its #790 holding.
First Mercantile Trust first reported a position in Fate Therapeutics in Q1 2018 and has held it in 13 quarters since.
First Mercantile Trust's Fate Therapeutics position peaked at $295K in Q2 2019.
265 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2021.

Based on First Mercantile Trust's 13F filing for Q3 2021, filed 24 Nov 2021.